Author:
Xiao Benli,Ge Yuzhen,Zhao Rui,Zhang Yewei,Guo Yi,Zhang Shilong,Li Bo,Qiu Peng,Chao Zheng,Zuo Shi
Subject
Pharmacology,Biochemistry
Reference37 articles.
1. Cancer statistics, 2023;Siegel;CA-Cancer J. Clin.,2023
2. Estimated projection of US cancer incidence and death to 2040;Rahib;JAMA Netw. Open,2021
3. N.C. Institute, Cancer Stat Facts: Pancreatic Cancer, 2023. https://seer.cancer.gov/statfacts/html/pancreas.html.
4. T. Conroy, P. Hammel, M. Hebbar, M. Ben Abdelghani, A.C. Wei, J.L. Raoul, L. Chone, E. Francois, P. Artru, J.J. Biagi, T. Lecomte, E. Assenat, R. Faroux, M. Ychou, J. Volet, A. Sauvanet, G. Breysacher, F. Di Fiore, C. Cripps, P. Kavan, P. Texereau, K. Bouhier-Leporrier, F. Khemissa-Akouz, J.L. Legoux, B. Juzyna, S. Gourgou, C.J. O'Callaghan, C. Jouffroy-Zeller, P. Rat, D. Malka, F. Castan, J.B. Bachet, G. Canadian Canc Trials, G.I.P.G. Unicanc, FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer, New Engl. J. Med. 379(25) (2018) 2395-2406.
5. PhaseIIstudy evaluating the association of gemcitabine, trastuzumab and erlotinib as first-line treatment in patients with metastatic pancreatic adenocarcinoma (GATE1);Assenat;Int. J. Cancer,2021